Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P4HTM | Q9NXG6 | 5/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.49 |
| ▸ | P4HA1 | P13674 | 1/20 | 0.47 |
| ▸ | MIF | P14174 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.45 |
| ▸ | XDH | P47989 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5755276 | 0.86 | P4HTM (0.63) | P4HTMP4HA1MIFKDM4EALDH1A1 | |
| SCHEMBL27943516 | 0.85 | OPRM1 (0.52) | KCNH2HRH3SCN9A | |
| SCHEMBL11410519 | 0.83 | KDM4E (0.65) | P4HTMP4HA1MIFKDM4EALDH1A1 | |
| SCHEMBL11411697 | 0.83 | P4HTM (0.58) | P4HTMP4HA1MIFKDM4EALDH1A1 | |
| SCHEMBL2417239 | 0.83 | P4HTM (0.51) | P4HTMP4HA1MIFKDM4EALDH1A1 | |
| SCHEMBL10933975 | 0.83 | CDH1 (0.54) | P4HTMHRH3P4HA1MIFKDM4E | |
| SCHEMBL11420514 | 0.83 | P4HTM (0.51) | P4HTMP4HA1MIFKDM4EALDH1A1 | |
| SCHEMBL753224 | 0.82 | MAPK1 (0.54) | KCNH2HRH3KDM4ESCN9AMAPK1 | |
| SCHEMBL11410233 | 0.82 | LIPE (0.50) | P4HTMP4HA1MIFKDM4E | |
| SCHEMBL30440468 | 0.82 | LIPE (0.50) | P4HTMP4HA1MIFKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4055021-B1 | HETEROCYCLIC RIP1 INHIBITORY COMPOUNDS | RIGEL PHARMACEUTICALS INC (US) | 2025-10-08 | — | — | EP | disclosed |
| CN-114728918-B | RIP1 inhibitory compounds and methods of making and using the same | 里格尔药品股份有限公司 | 2025-06-17 | — | — | CN | disclosed |
| EP-4025568-B1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIGEL PHARMACEUTICALS INC (US) | 2025-05-14 | — | — | EP | disclosed |
| EP-4025574-B1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIGEL PHARMACEUTICALS INC (US) | 2025-05-07 | — | — | EP | disclosed |
| US-20250092057-A1 | HETEROCYCLIC RIP1 INHIBITORY COMPOUNDS | RIGEL PHARMACEUTICALS, INC. | 2025-03-20 | — | — | US | disclosed |
| CN-115298184-B | Heterocyclic RIP1 inhibiting compounds | 里格尔药品股份有限公司 | 2025-01-28 | — | — | CN | disclosed |
| US-20240368119-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIGEL PHARMACEUTICALS, INC. | 2024-11-07 | — | — | US | disclosed |
| US-20230322732-A1 | RIP1 Inhibitory Compounds and Methods for Making and Using the Same | RIGEL PHARMACEUTICALS, INC. | 2023-10-12 | — | — | US | disclosed |
| US-20230143161-A1 | HETEROCYCLIC RIP1 INHIBITORY COMPOUNDS | RIGEL PHARMACEUTICALS, INC. | 2023-05-11 | — | — | US | disclosed |
| US-20230112865-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | MIDCAP FINANCIAL TRUST | 2023-04-13 | — | — | US | disclosed |
| US-20170066754-A1 | ANTIVIRAL AGENT | SHIONOGI & CO., LTD. (JP) | 2017-03-09 | — | — | US | disclosed |
| US-9572813-B2 | Antiviral agent | SHIONOGI & CO., LTD. (JP) | 2017-02-21 | — | — | US | disclosed |
| EP-3042894-A1 | ANTIVIRAL AGENT | SHIONOGI & CO., LTD. (JP) | 2016-07-13 | — | — | EP | disclosed |
| US-20150202208-A1 | ANTIVIRAL AGENT | SHIONOGI & CO., LTD. (JP) | 2015-07-23 | — | — | US | disclosed |
| EP-1422218-B1 | ANTIVIRAL AGENT | SHIONOGI & CO (JP) | 2012-03-21 | — | — | EP | disclosed |
| EP-2181985-B1 | Antiviral Agent | SHIONOGI & CO (JP) | 2011-10-26 | — | — | EP | disclosed |
| EP-2266958-A1 | Antiviral agent | SHIONOGI & CO., LTD. (JP) | 2010-12-29 | — | — | EP | disclosed |
| EP-2181985-A1 | Antiviral Agent | SHIONOGI & CO., LTD. (JP) | 2010-05-05 | — | — | EP | disclosed |
| US-20040229909-A1 | Antiviral agent | SHIONOGI & CO., LTD. (JP) | 2004-11-18 | — | — | US | disclosed |
| EP-1422218-A1 | ANTIVIRAL AGENT | SHIONOGI & CO., LTD. (JP) | 2004-05-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230143161-A1 | HETEROCYCLIC RIP1 INHIBITORY COMPOUNDS | RIPK1, RIPK2, RIPK3 | P4HTM 4725/4885KCNH2 4562/4885HRH3 3236/4885 |
| US-20240368119-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIPK1, RIPK2, RIPK3 | P4HTM 4684/4885KCNH2 4724/4885HRH3 3422/4885 |
| US-20040229909-A1 | Antiviral agent | ZC3HAV1, ZC3HAV1L, DUT | P4HTM 2775/4885KCNH2 3468/4885HRH3 2859/4885 |
| US-20230112865-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIPK1, RIPK2, RIPK3 | P4HTM 4684/4885KCNH2 4724/4885HRH3 3422/4885 |
| US-20230322732-A1 | RIP1 Inhibitory Compounds and Methods for Making and Using the Same | RIPK1, RIPK2, RIPK3 | P4HTM 4684/4885KCNH2 4724/4885HRH3 3422/4885 |
| US-20250092057-A1 | HETEROCYCLIC RIP1 INHIBITORY COMPOUNDS | RIPK1, RIPK2, RIPK3 | P4HTM 4725/4885KCNH2 4562/4885HRH3 3236/4885 |
| US-20150202208-A1 | ANTIVIRAL AGENT | ZC3HAV1, ZC3HAV1L, CCNI | P4HTM 2766/4885KCNH2 3830/4885HRH3 2614/4885 |
| US-20170066754-A1 | ANTIVIRAL AGENT | ZC3HAV1, ZC3HAV1L, CCNI | P4HTM 2766/4885KCNH2 3830/4885HRH3 2614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.